Characteristics of patients randomized to second-line therapy
Characteristic . | Non-ATG . | ATG . | P . |
|---|---|---|---|
| Recipient sex, no. male/no. female | 17/17 | 15/12 | .6 |
| Median recipient age, y (range) | 33 (2-64) | 36 (2-63) | .4 |
| Donor type, no. | |||
| HLA-identical sibling | 16 | 14 | — |
| Unrelated | 18 | 13 | .7 |
| Diagnosis, no. | |||
| AML + ALL | 18 | 12 | — |
| CML | 12 | 7 | — |
| LY/MM | 1 | 4 | — |
| Other | 3 | 4 | .3 |
| Advanced phase | 22 (67%) | 16 (59%) | .4 |
| 14 or fewer days of first-line treatment, no. | 7 | 8 | .4 |
| Timing of GvHD, ≤ 14 d after transplantation | 7 | 7 | .4 |
| GvHD grade at randomization, no. | |||
| I | 7 | 4 | — |
| II | 19 | 16 | — |
| III | 8 | 7 | .5 |
| Skin GvHD day 5, no. | 33* | 26 | .3 |
| Liver GvHD day 5, no. | 14 | 7 | .2 |
| Gut GvHD day 5, no. | 17 | 14 | .9 |
| Response at day +30, no. (%) | |||
| Resolution of GvHD | 8 (24) | 9 (33) | — |
| Partial resolution | 8 (24) | 6 (22) | — |
| Stable GvHD | 13 (38) | 5 (19) | — |
| Worsened | 4 (12) | 2 (7) | — |
| Dead | 1 (3) | 5 (19) | — |
| Alive | 13 (38) | 9 (33) | .9 |
| Dead TRM | 14 (41) | 16 (59) | .2 |
| Dead relapse | 7 (21) | 2 (8) | .1 |
Characteristic . | Non-ATG . | ATG . | P . |
|---|---|---|---|
| Recipient sex, no. male/no. female | 17/17 | 15/12 | .6 |
| Median recipient age, y (range) | 33 (2-64) | 36 (2-63) | .4 |
| Donor type, no. | |||
| HLA-identical sibling | 16 | 14 | — |
| Unrelated | 18 | 13 | .7 |
| Diagnosis, no. | |||
| AML + ALL | 18 | 12 | — |
| CML | 12 | 7 | — |
| LY/MM | 1 | 4 | — |
| Other | 3 | 4 | .3 |
| Advanced phase | 22 (67%) | 16 (59%) | .4 |
| 14 or fewer days of first-line treatment, no. | 7 | 8 | .4 |
| Timing of GvHD, ≤ 14 d after transplantation | 7 | 7 | .4 |
| GvHD grade at randomization, no. | |||
| I | 7 | 4 | — |
| II | 19 | 16 | — |
| III | 8 | 7 | .5 |
| Skin GvHD day 5, no. | 33* | 26 | .3 |
| Liver GvHD day 5, no. | 14 | 7 | .2 |
| Gut GvHD day 5, no. | 17 | 14 | .9 |
| Response at day +30, no. (%) | |||
| Resolution of GvHD | 8 (24) | 9 (33) | — |
| Partial resolution | 8 (24) | 6 (22) | — |
| Stable GvHD | 13 (38) | 5 (19) | — |
| Worsened | 4 (12) | 2 (7) | — |
| Dead | 1 (3) | 5 (19) | — |
| Alive | 13 (38) | 9 (33) | .9 |
| Dead TRM | 14 (41) | 16 (59) | .2 |
| Dead relapse | 7 (21) | 2 (8) | .1 |
For patients not given ATG, n = 34; for patients given ATG, n = 27.
AML indicates acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myelogenous leukemia; LY, lymphoma; MM, multiple myeloma; —, not applicable.
Number of patients with skin, liver, or gut GvHD on day 5 (at the time of randomization).